AR040201A1 - Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen - Google Patents

Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen

Info

Publication number
AR040201A1
AR040201A1 ARP030102093A ARP030102093A AR040201A1 AR 040201 A1 AR040201 A1 AR 040201A1 AR P030102093 A ARP030102093 A AR P030102093A AR P030102093 A ARP030102093 A AR P030102093A AR 040201 A1 AR040201 A1 AR 040201A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
carbon atoms
independently
fluoradas
Prior art date
Application number
ARP030102093A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR040201A1 publication Critical patent/AR040201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Abstract

Benzoilguanidinas cicloalquilderivadas fluoradas de la fórmula (1) son adecuadas como medicamentos antiarrítmicos con un componente cardioprotector para profilaxis de infartos y tratamiento de infartos y para el tratamiento de angina pectoris. También inhiben preventivamente los procesos patofisiológicos asociados con el desarrollo del dano inducido por isquemia, en particular en el desencadenamiento de arritmias cardíacas inducidas por isquemia y de fallo cardíaco. El uso de estos compuestos para producir un medicamento y medicamento que los contiene. Reivindicación 1: Una benzoilguanidinas cicloalquilderivada fluorada de la fórmula (1) en la que los significados son: X oxígeno, azufre o NR6; R6 es hidrógeno, alquilo que tiene 1, 2, 3 ó 4 átomos de carbono o (CH2)k-CF3; k es 0, 1, 2 ó 3; m es 0, 1, 2 ó 3; n es 0, 1, 2 ó 3; p 0, 1, 2 ó 3; q es 1, 2 ó 3; r es 0, 1, 2 ó 3; donde el total de m, n, p, q y r es al menos 2; R1 es hidrógeno, alquilo que tiene 1, 2, 3 ó 4 átomos de carbono, F, Cl, -OR7, -NR8R9 o -CsF2s+1; R7, R8 y R9 independientemente uno del otro, hidrógeno, alquilo 1, 2 ó 3 átomos de carbono o (CH2)t-CF3; s es 1, 2, 3 ó 4; t es 0, 1, 2, 3 ó 4; R2 es hidrógeno, F, Cl, alquilo que tiene 1, 2, 3 ó 4 átomos de carbono o CF3; R3 hidrógeno, F, Cl, alquilo que tiene 1, 2, 3 ó 4 átomos de carbono o SOuR10; u es 0, 1 ó 2; R10 alquilo que tiene 1, 2, 3 ó 4 átomos de carbono o NR11R12; R11 y R12 independientemente uno del otro, hidrógeno o alquilo que tiene 1, 2, 3 ó 4 átomos de carbono; R4 hidrógeno, alquilo que tiene 1, 2, 3 ó 4 átomos de carbono, F, Cl, -OR13, -NR14R15 o -CvF2v+1; R13, R14 y R15 independientemente uno del otro, hidrógeno, alquilo que tiene 1, 2 ó 3 átomos de carbono o (CH2)w-CF3; v 1, 2, 3 ó 4; w 0, 1, 2, 3 ó 4; R5 es hidrógeno o F; y sus sales aceptables farmacéuticamente.
ARP030102093A 2002-06-13 2003-06-11 Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen AR040201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226462A DE10226462A1 (de) 2002-06-13 2002-06-13 Fluorierte Cycloalkyl-derivatisierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
AR040201A1 true AR040201A1 (es) 2005-03-16

Family

ID=29594510

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102093A AR040201A1 (es) 2002-06-13 2003-06-11 Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen

Country Status (26)

Country Link
EP (2) EP2103598A1 (es)
JP (1) JP4383343B2 (es)
KR (1) KR20050010052A (es)
CN (1) CN1295213C (es)
AR (1) AR040201A1 (es)
AT (1) ATE442353T1 (es)
AU (1) AU2003250821B8 (es)
BR (1) BR0312134A (es)
CA (1) CA2489245A1 (es)
DE (2) DE10226462A1 (es)
DK (1) DK1515947T3 (es)
ES (1) ES2333216T3 (es)
HK (1) HK1076449A1 (es)
HR (1) HRP20041175A2 (es)
MA (1) MA27234A1 (es)
MX (2) MXPA04011361A (es)
MY (1) MY130810A (es)
NO (1) NO20050078L (es)
PE (1) PE20040559A1 (es)
PL (1) PL372054A1 (es)
PT (1) PT1515947E (es)
RS (1) RS105904A (es)
RU (1) RU2305093C2 (es)
TW (1) TWI291460B (es)
WO (1) WO2003106410A1 (es)
ZA (1) ZA200409418B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102004043938A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102004054847A1 (de) * 2004-11-13 2006-05-24 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0912118A2 (pt) * 2008-06-06 2015-11-03 Ucb Pharma Sa composto, composição farmacêutica, e, intermediário sintético
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
BR112012003973A2 (pt) 2009-08-26 2015-09-08 Sanofi Sa hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета
CN113274380A (zh) * 2021-05-13 2021-08-20 武汉理工大学 S0859在制备治疗脑缺血再灌注损伤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665739A (en) * 1992-12-15 1997-09-09 Hoechst Aktiengesellschaft Substituted benzoylguanidines, process and their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them
TW250479B (es) * 1992-12-15 1995-07-01 Hoechst Ag
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6057322A (en) * 1995-01-30 2000-05-02 Hoechst Aktiengesellschaft Basically-substituted benzoylguanidines, a process for preparing them, their use as a medicament or diagnostic agent, and a medicament containing them

Also Published As

Publication number Publication date
TWI291460B (en) 2007-12-21
HK1076449A1 (en) 2006-01-20
ATE442353T1 (de) 2009-09-15
MY130810A (en) 2007-07-31
DE10226462A1 (de) 2003-12-24
AU2003250821B8 (en) 2008-10-02
EP2103598A1 (de) 2009-09-23
KR20050010052A (ko) 2005-01-26
HRP20041175A2 (en) 2005-08-31
EP1515947B1 (de) 2009-09-09
DE50311897D1 (de) 2009-10-22
MXPA04011361A (es) 2005-02-14
PT1515947E (pt) 2009-11-11
PE20040559A1 (es) 2004-10-22
RU2005100508A (ru) 2005-07-20
CN1295213C (zh) 2007-01-17
AU2003250821B2 (en) 2008-09-11
CN1659139A (zh) 2005-08-24
RS105904A (en) 2007-02-05
TW200404768A (en) 2004-04-01
PL372054A1 (en) 2005-07-11
MA27234A1 (fr) 2005-02-01
EP1515947A1 (de) 2005-03-23
JP4383343B2 (ja) 2009-12-16
BR0312134A (pt) 2005-04-05
MXPA04012231A (es) 2005-02-25
NO20050078L (no) 2005-01-06
WO2003106410A1 (de) 2003-12-24
AU2003250821A1 (en) 2003-12-31
RU2305093C2 (ru) 2007-08-27
ES2333216T3 (es) 2010-02-18
JP2005529182A (ja) 2005-09-29
ZA200409418B (en) 2006-05-31
CA2489245A1 (en) 2003-12-24
DK1515947T3 (da) 2010-01-18

Similar Documents

Publication Publication Date Title
AR040201A1 (es) Benzoilguanidinas cicloalquilderivadas fluoradas, su uso como medicamento y medicamentos que las contienen
SV2003000876A (es) Quinazolinas como inhibidores de mmp-13
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
PE20060363A1 (es) DERIVADOS DE TETRAAZABENZO[e]AZULENO Y SUS ANALOGOS
AR032752A1 (es) Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa
UY27835A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
AR015526A1 (es) Compuestos para el tratamiento de la isquemia; uso para la preparacion de medicamentos, composicion farmaceutica, combinacion farmaceutica, equipoconteniendo los mismos
AR048820A1 (es) Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3)
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
UY27446A1 (es) Nuevos compuestos
AR039335A1 (es) Tableta de carga de droga alta
AR009519A1 (es) Compuesto analogo de carbazol, formulacion farmaceutica que lo comprende y su uso para fabricar un medicamento.
TW200505441A (en) Non-nucleoside reverse transcriptase inhibitorsⅠ
AR058380A1 (es) Inhibidores del factor viia macrociclicos utiles como anticoagulantes
NO20014225L (no) Nye sykliske tetrapeptid-derivater og anvendelse av dem som legemidler
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
PE20211205A1 (es) Inhibidores de la interaccion proteina-proteina keap1-nrf2
AR074700A1 (es) Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades
AR041218A1 (es) Derivados de indolilo, un proceso para su preparacion, composicion farmaceutica que lo contiene y uso del compuesto para preparar un medicamento
NO20045447L (no) Pentafluorsulfanyl-benzoylguanidiner, fremgangsmate for deres fremstilling, deres anvendelse som legemiddel eller diagnostisk middel samt medikamenter inneholdende disse
ES2122749T3 (es) Catalizador para la (co)polimerizacion de olefinas y procedimiento para su empleo.
TNSN06116A1 (en) Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same
AR007299A1 (es) 1-naftoilguanidinas sustituidas, procedimiento para su preparacion, su empleo para la preparacion de un medicamento y agente curativo y terapeuticoque las contiene
UY28358A1 (es) Derivados de 3-(guanidinocarbonil)heterociclos, procedimiento de preparación y compuestos intermedios de este procedimiento, su uso como medicamentos, y composiciones farmaceuticas que los incluyen.
AR040565A1 (es) Derivados de 3- guanidocarbonil 1-heteroaril - indol, procedimiento de preparacion, su uso como medicamentos y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure